Home › NCT07630402

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Who can join

Ages 18 to 79 · Women

Inclusion Criteria:

* Female sex, age 18-79 years.
* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
* Baseline LVEF ≥ 55 % by 2-D echocardiography.
* Ability to provide informed consent.

Exclusion Criteria:

* Prior HF, myocardial infarction, or cardiomyopathy.
* Atrial fibrillation or significant valvular heart disease.
* Cumulative anthracycline dose ≥ 250 mg/m².
* Pregnancy or lactation.
* Inability to comply with study procedures.

About the study

The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).

What is being tested

• Echocardiogram (procedure)

Sponsor: University of Rochester · Participants: 20 · Started: Nov 17, 2025

Contact the study team

• Kaily LaForce · Phone: 585-274-2808

Official record on ClinicalTrials.gov — NCT07630402

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.